Abstract
It was only in December 2008 that the European Union regulated the approval procedure for tissue engineered products (TEPs). Due to this regulation, TEP is classified as an advanced therapy medicinal product and as such may be recognized as a tool in pharmaceutical biotechnology. This paper gives a short review of the concept, the experimental evaluation and the clinical potency of tissue engineering (TE), with a particular focus on bone tissue engineered products. After a period of great enthusiasm about TE at the end of the 20th century a slight disappointment followed in the early 2000s. The review refers also to the continuously growing scientific interest, accompanied by the still modest representation of TEPs on the medical market. Some remarks are given on a bench-to-clinic road, including criticism concerning data originating from animal experiments. An attempt is made to foresee the still promising future of bone tissue engineered products (BTEPs) in practical use.
Keywords: Bone, Tissue engineering, Medicinal product, Stem cells, Scaffold, intrinsic bioactivity, cytokines, allogenic transplantation, human periosteal cells, autologous marrow stromal cells, sheep metatarsals, pre-cultured cells, cell-based therapy, bone morphogenic proteins (BMP), calcium phosphate ceramics, human embryonic stem cells (hESCs)
Current Pharmaceutical Biotechnology
Title: Bone Tissue Engineering – A Field For New Medicinal Products?
Volume: 12 Issue: 11
Author(s): Malgorzata Lewandowska-Szumiel and Joanna Wojtowicz
Affiliation:
Keywords: Bone, Tissue engineering, Medicinal product, Stem cells, Scaffold, intrinsic bioactivity, cytokines, allogenic transplantation, human periosteal cells, autologous marrow stromal cells, sheep metatarsals, pre-cultured cells, cell-based therapy, bone morphogenic proteins (BMP), calcium phosphate ceramics, human embryonic stem cells (hESCs)
Abstract: It was only in December 2008 that the European Union regulated the approval procedure for tissue engineered products (TEPs). Due to this regulation, TEP is classified as an advanced therapy medicinal product and as such may be recognized as a tool in pharmaceutical biotechnology. This paper gives a short review of the concept, the experimental evaluation and the clinical potency of tissue engineering (TE), with a particular focus on bone tissue engineered products. After a period of great enthusiasm about TE at the end of the 20th century a slight disappointment followed in the early 2000s. The review refers also to the continuously growing scientific interest, accompanied by the still modest representation of TEPs on the medical market. Some remarks are given on a bench-to-clinic road, including criticism concerning data originating from animal experiments. An attempt is made to foresee the still promising future of bone tissue engineered products (BTEPs) in practical use.
Export Options
About this article
Cite this article as:
Lewandowska-Szumiel Malgorzata and Wojtowicz Joanna, Bone Tissue Engineering – A Field For New Medicinal Products?, Current Pharmaceutical Biotechnology 2011; 12 (11) . https://dx.doi.org/10.2174/138920111798376941
DOI https://dx.doi.org/10.2174/138920111798376941 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dual Acting Anti-Inflammatory Drugs
Current Topics in Medicinal Chemistry Programs to Facilitate Tuberculosis Drug Discovery: The Tuberculosis Antimicrobial Acquisition and Coordinating Facility
Infectious Disorders - Drug Targets Microarray Profiling Analysis Uncovers Common Molecular Mechanisms of Rubella Virus, Human Cytomegalovirus, and Herpes Simplex Virus Type 2 Infections in ECV304 Cells
Current Molecular Medicine Cholesteryl Ester Transfer Protein (CETP) Inhibitors
Current Topics in Medicinal Chemistry Development of Dry Powder Inhalers
Recent Patents on Drug Delivery & Formulation Current State of Saliva Biomarkers for Aging and Alzheimer’s Disease
Current Alzheimer Research Effect of Oxidative Stress on the Pharmacokinetics of Clomipramine in Rats Treated with Ferric-Nitrilotriacetate
Drug Metabolism Letters Practical Review of Mechanical Ventilation in Adults and Children in the Operating Room and Emergency Department
Reviews on Recent Clinical Trials Fenofibrate: Metabolic and Pleiotropic Effects
Current Vascular Pharmacology Unfoldomics of Human Genetic Diseases: Illustrative Examples of Ordered and Intrinsically Disordered Members of the Human Diseasome
Protein & Peptide Letters Intracardiac Origin of Heart Rate Variability, Pacemaker Funny Current and their Possible Association with Critical Illness
Current Cardiology Reviews Synthesis and Anticancer Studies of Novel N-benzyl Pyridazino ne Derivatives
Letters in Drug Design & Discovery Recommendations for Severe Hypertriglyceridemia Treatment, are there New Strategies?
Current Vascular Pharmacology Bradykinin B1 Receptor Antagonists as Novel Analgesics: A Retrospective of Selected Medicinal Chemistry Developments
Current Topics in Medicinal Chemistry Genetically Engineered Mouse Models for Drug Discovery: New Chemical Genetic Approaches
Current Drug Discovery Technologies The Role of C-Reactive Protein in Atherosclerotic Cardiovascular Disease: An Overview
Current Vascular Pharmacology Homocysteine and Heart Failure: An Overview
Recent Patents on Cardiovascular Drug Discovery Molecular Targets of Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) Impact of Macrophages in Atherosclerosis
Current Medicinal Chemistry The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design